Jacobs Levy Equity Management
IART icon

Jacobs Levy Equity Management’s Integra LifeSciences IART Stock Holding History

Jacobs Levy Equity Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,584
Closed -$722K – 993
2023
Q4 		$722K Hold
16,584
– – ﹤0.01% 777
2023
Q3 		$633K Buy
+16,584
New +$698K ﹤0.01% 755
2013
Q4 		– Sell
-37,676
Closed -$620K – 982
2013
Q3 		$620K Sell
37,676
-65,565
-64% -$1.05M 0.01% 632
2013
Q2 		$1.55M Buy
+103,241
New +$1.51M 0.03% 476

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jacobs Levy Equity Management's IART Position: Q1 2024 in Review

Jacobs Levy Equity Management sold out of Integra LifeSciences (IART) in Q1 2024, closing a stake of 16,584 shares — an estimated $722K sold.

Jacobs Levy Equity Management first reported a position in IART in Q2 2013 and held it in 4 quarters. The position peaked at $1.55M in Q2 2013. 281 funds tracked by Wall St. Rank hold IART as of Q1 2024.

  • Jacobs Levy Equity Management reported no remaining Integra LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 16,584 Integra LifeSciences shares in Q1 2024, an estimated $722K.
  • Jacobs Levy Equity Management first reported a position in Integra LifeSciences in Q2 2013 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Integra LifeSciences position peaked at $1.55M in Q2 2013.
  • 281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2024, filed 15 May 2024.